Clinical Trial Update: Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion and posting of results for a Phase 3 study of sorafenib (BAY43-9006) in patients with unresectable and/or meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED | Results posted: 2011-12-14